I’d buy both the Glaxo share price and AstraZeneca’s growth prospects today

AstraZeneca plc (LON: AZN) has been pulling ahead of GlaxoSmithKline plc (LSE: GSK) but Harvey Jones says that could change.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I remember the days when everybody wanted pharmaceutical giant GlaxoSmithKline (LSE: GSK) in their dividend portfolio. Now investors are more sceptical.

Glax on the tracks

The Glaxo share price has had a bumpy ride for the last six years, although it is up 13% year-to-date and jumped more than 1% after today’s results showed a rise in second-quarter sales and profits, with full-year earnings now set to drop less than expected.

FTSE 100 pharmaceutical rival AstraZeneca (LSE: AZN) has had a much better time of it lately, its share price up almost 45% in five years to hit record highs. It is up 5% this morning after a far more bullish set of results than Glaxo’s, with first-half product sales up 12% to $11.18bn, a rise of 17% at constant exchange rates.

Astra’s strong

AstraZeneca said sales growth accelerated in Q2, rising by 14% to $5.72bn (19% in constant currency). Better still, they grew in every region with all three therapy areas delivering an encouraging performance.

Highlights included 51% oncology sales growth and 34% sales growth in China to $1.17bn (a whopping 44% at constant exchange rates), while US sales rose 16% to $1.88bn, and even Europe returned to growth up 1% to $1.04bn.

Investors will have been excited by talk of further positive pipeline developments, with the second half of the year anticipated to be an exceptionally busy period”.

Glaxo grows too

Glaxo’s results were good, although not as good. Q2 group turnover up 7% to £7.8bn, or 5% at constant exchange rates. Its Vaccines arm did particularly well, with turnover up 26% to £1.585bn at actual exchange rates, driven by meningitis vaccine Shingrix.

Consumer Healthcare turnover was up a healthy 5% to £1.9bn, although Glaxo’s key Pharmaceuticals division grew at a slower pace of 2%, to £4.3bn.

Total operating profit was £1.48bn in the quarter, up from £779m in 2018. However, once accounting for restructuring charges and write-downs, adjusted operating profit rose 3% to £2.17m at actual exchange rates.

AstraZeneca is now the bigger group by market cap, £87.93bn against £83.44bn.

But which to buy?

So the smart money says buy AstraZeneca?

I’m not so sure, and neither is my colleague Roland Head, who recently warned of the group’s surging debt, up from $7.8bn four years ago to $13bn in today’s report. Management is whittling it down, to be fair, as net debt stood at $15.34bn one year ago.

However, with the AstraZeneca share price trading at 22.7 times earnings, investors are pricing an awful lot of growth into the stock.

Glaxo is notably cheaper at 14.8 times forecast earnings. Operationally, it is in a better place than before. It offers a higher dividend income too, with a forecast yield 4.8% and cover of 1.4, against AstraZeneca’s 3.5% yield with cover of 1.2. Don’t expect too much progression from either, both have been holding their dividends for years while pumping money into replenishing their pipelines.

Momentum is on AstraZeneca’s side as it races ahead of Glaxo but high investor hopes mean it cannot afford any slippage.

If I had to buy one, it would be Glaxo, though. With luck, you might catch it at an earlier stage in its recovery cycle.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »